On March 2, 2016 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported the completion of patient enrollment in the Company’s Phase II extension study of its investigational product ImmunoPulse IL-12 for the treatment of advanced melanoma (Press release, OncoSec Medical, MAR 2, 2016, View Source [SID:1234509333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial’s objective is to evaluate an alternate dosing frequency and additional biomarkers to provide further scientific understanding of ImmunoPulse IL-12 in an extension of the OMS-I100 Phase II melanoma trial. The Company expects to report consolidated data from the OMS-I100 and extension studies by Q3 2016.

"We are committed to improving the lives of patients with advanced melanoma and are pleased to have completed enrollment in this Phase II study," said Punit Dhillon, President and CEO of OncoSec. "Completing enrollment in this study is an important step in the development for ImmunoPulse IL-12 as it allows us to build upon our positive Phase I and II results and inform our ongoing and future trials. There is a significant opportunity to bring forward a new generation of intratumoral immunotherapies for patients with melanoma who typically don’t respond to first-line immunotherapies due to a low-TIL (tumor-infiltrating lymphocyte) phenotype. Our intention is to use the results from this study along with data from our OMS-I100 Phase II trial to formulate a combination registration path for ImmunoPulse IL-12 in melanoma."

The objective of the extension study is to assess the safety and efficacy of a six-week treatment cycle with ImmunoPulse IL-12 in 21 patients with advanced melanoma. The protocol extension provides an opportunity to assess whether more frequent treatment with ImmunoPulse IL-12 can provide additional clinical benefit to patients. The details of the trial can be found at www.clinicaltrials.gov.